Abdul Waseh Basit (born November 1971) is a professor of pharmaceutics at University College London,[1] and founder of two pharmaceutical biotechnology companies spinning out of UCL. Basit is interested in particular in oral drug delivery and pharmaceutical three-dimensional (3D) printing.[2][3][4]
Abdul W. Basit | |
|---|---|
| Alma mater | University of Bath (BPharm); The School of Pharmacy, University of London (PhD) |
| Known for | 3D printing of pharmaceuticals
Drug delivery Gastroenterology |
| Scientific career | |
| Fields | Pharmaceutics |
| Institutions | University College London |
| Doctoral advisor | John Michael Newton |
Education and career
editBasit graduated with a first class honours degree in pharmacy in 1993 from the University of Bath and undertook his pharmacy pre-registration training at Pfizer Pharmaceuticals, becoming a registered pharmacist in 1994.[5][6] He joined the School of Pharmacy, University of London (now UCL School of Pharmacy) in 1994 where he completed his PhD in pharmaceutics and was appointed professor in pharmaceutics in 2010.
Basit leads a research group based in University College London that investigates gastroenterology,[7][8] metabolic potential of the gastrointestinal microbiota on drugs,[9][10] and the development of modern pharmaceutical manufacturing techniques using three-dimensional (3D) printing.[11][12] In 2016, Basit was appointed the European editor of the International Journal of Pharmaceutics.[13] His h-index is currently 68[as of?] with over 13,000 citations.[14]
In 2014, Basit founded FabRx with Simon Gaisford, Alvaro Goyanes Goyanes and Bill Lindsay spinning out from University College London. The firm is a biotechnology company that is developing 3D printing technology for medicines and medical devices. In 2017, FabRx was awarded the TCT Best Start-Up Award.[15] In 2019, it received over £600,000 from Innovate UK to develop a 3D printer for the production of personalised medicines.[16] In 2016, Basit co-founded Intract Pharma; the firm is a pharmaceutical company that provides licensable technologies for targeted delivery in the gastrointestinal tract. In 2018, it received £1.4 million from Innovate UK to develop a scalable manufacturing process for oral antibody products.[17][18]
Awards and honours
edit- 2014 Academy of Pharmaceutical Sciences AstraZeneca Award[19]
Publications
edit- 3D Printing of Pharmaceuticals[20]
References
edit- ^ UCL (2018-04-25). "Professor Abdul Basit". UCL School of Pharmacy. Retrieved 2020-01-07.
- ^ "Abdul Basit - Google Scholar Citations". scholar.google.co.uk. Retrieved 2020-01-07.
- ^ "Abdul W Basit, Author at ONdrugDelivery". ONdrugDelivery. Retrieved 2020-01-07.
- ^ "Abdul Basit". scholar.google.com. Retrieved 2020-10-14.
- ^ "Professor Abdul Basit". www.ucl.ac.uk. 25 April 2018. Retrieved 2020-01-07.
- ^ "Joint Pharmaceutical Analysis Group". www.jpag.org. Retrieved 2020-01-07.
- ^ McConnell, Emma L; Basit, Abdul W; Murdan, Sudaxshina (2008-01-01). "Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments". Journal of Pharmacy and Pharmacology. 60 (1): 63–70. doi:10.1211/jpp.60.1.0008. ISSN 0022-3573. PMID 18088506. S2CID 12647907.
- ^ McConnell, Emma L.; Fadda, Hala M.; Basit, Abdul W. (2008-12-08). "Gut instincts: Explorations in intestinal physiology and drug delivery". International Journal of Pharmaceutics. 364 (2): 213–226. doi:10.1016/j.ijpharm.2008.05.012. ISSN 0378-5173. PMID 18602774.
- ^ Sousa, Tiago; Paterson, Ronnie; Moore, Vanessa; Carlsson, Anders; Abrahamsson, Bertil; Basit, Abdul W. (2008-11-03). "The gastrointestinal microbiota as a site for the biotransformation of drugs". International Journal of Pharmaceutics. 363 (1): 1–25. doi:10.1016/j.ijpharm.2008.07.009. ISSN 0378-5173. PMID 18682282.
- ^ Wilson, Peter J; Basit, Abdul W (2005-08-26). "Exploiting gastrointestinal bacteria to target drugs to the colon: An in vitro study using amylose coated tablets". International Journal of Pharmaceutics. Festschrift in Honour of the 65th Birthday of Professor A.T. Florence. 300 (1): 89–94. doi:10.1016/j.ijpharm.2005.05.010. ISSN 0378-5173. PMID 16023805.
- ^ Goyanes, Alvaro; Buanz, Asma B. M.; Basit, Abdul W.; Gaisford, Simon (2014-12-10). "Fused-filament 3D printing (3DP) for fabrication of tablets". International Journal of Pharmaceutics. 476 (1): 88–92. doi:10.1016/j.ijpharm.2014.09.044. ISSN 0378-5173. PMID 25275937.
- ^ Goyanes, Alvaro; Robles Martinez, Pamela; Buanz, Asma; Basit, Abdul W.; Gaisford, Simon (2015-10-30). "Effect of geometry on drug release from 3D printed tablets". International Journal of Pharmaceutics. 494 (2): 657–663. doi:10.1016/j.ijpharm.2015.04.069. ISSN 0378-5173. PMID 25934428.
- ^ International Journal of Pharmaceutics Editorial Board.
- ^ "Abdul Basit". scholar.google.com. Retrieved 2021-04-27.
- ^ Davies, Sam (2017-12-04). "FabRx launches Kickstarter campaign as it looks to 3D print medicine for children". TCT Magazine. Retrieved 2020-01-07.
- ^ "FabRx Awarded Innovate UK Grant to Design the World's First Personalised Medicine 3D Printer". FabRx. 2019-04-14. Retrieved 2020-01-07.
- ^ UCL (2019-03-07). "Intract awarded Innovate UK grant to make oral antibody formulation using Soteria® technology". UCL School of Pharmacy. Retrieved 2020-01-07.
- ^ "Intract Pharma awarded £1.4m grant to develop antibodies". EPM Magazine. 2018-12-28. Retrieved 2020-01-07.
- ^ UCL (2014-08-21). "Professor Abdul Basit receives Academy of Pharmaceutical Sciences Award". UCL School of Pharmacy. Retrieved 2020-01-07.
- ^ Basit, Abdul; Gaisford, Simon, eds. (2018). 3D Printing of Pharmaceuticals. AAPS Advances in the Pharmaceutical Sciences Series. Springer International Publishing. ISBN 978-3-319-90754-3.